Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
A counter-irritant is not a specific molecular target but rather a pharmacological class of substances applied topically to the skin to alleviate pain in underlying muscles, joints, or organs. These agents work by inducing a mild, localized inflammatory reaction or sensory stimulation that serves to distract the central nervous system from more severe, deep-seated pain signals (StatPearls, 2023). This phenomenon is largely explained by the 'gate control theory' of pain, where the activation of large-diameter sensory fibers in the skin inhibits the transmission of pain signals from smaller fibers in the spinal cord (Melzack & Wall, 1965). At the molecular level, counter-irritants typically interact with various Transient Receptor Potential (TRP) channels on nociceptors, such as TRPV1 (activated by capsaicin), TRPM8 (activated by menthol), and TRPA1 (activated by wintergreen oil/methyl salicylate) (Nilius & Szallasi, 2014, Nature Reviews Drug Discovery). Beyond simple sensory distraction, some counter-irritants like capsaicin achieve long-term analgesia by causing the depletion of Substance P from local sensory nerve endings, thereby reducing the transmission of pain stimuli to the brain (NIH, PubChem). Others, known as rubefacients, induce vasodilation and increased blood flow to the affected area, which may help in the healing of underlying tissues. While generally safe for external use, these substances can cause significant irritation, blistering, or systemic toxicity if used inappropriately or on broken skin. They remain a staple in the management of minor musculoskeletal conditions, including arthritis, simple backache, and sports-related strains.
Stimulation of sensory nerve endings in the skin to create a mild irritation or inflammatory response, which distracts from or 'gates' the perception of deeper-seated pain (Gate Control Theory). Specific agents act as agonists for TRP channels (e.g., TRPV1, TRPM8), inducing sensations of heat or cold and increasing local blood flow through vasodilation.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Counter-irritant.